Phosphodiesterase Targets for Cognitive Dysfunction and Schizophrenia--a New York Academy of Sciences Meeting.
The Phosphodiesterase Targets for Cognitive Dysfunction and Schizophrenia meeting, held in New York, included topics covering new therapeutic developments in the field of PDE inhibitors for the treatment of cognitive dysfunction. This conference report highlights selected presentations on inhibitors of PDE1, PDE4, PDE5, PDE8, PDE9 and PDE10 for schizophrenia-related cognitive disorders. Investigational drugs discussed include PF-2545920 (Pfizer Inc).
Zhang
Han Ting
HT
West Virginia University School of Medicine, One Medical Center Drive, PO Box 9137, Morgantown, WV 26506-9137, USA. hzhang@hsc.wvu.edu
D000818:Animals; D003071:Cognition / Q000187:drug effects*; D003072:Cognition Disorders / Q000188:drug therapy* / Q000201:enzymology / Q000523:psychology; D000242:Cyclic AMP / Q000378:metabolism; D055808:Drug Discovery; D004345:Drug Industry; D015507:Drugs, Investigational / Q000737:chemistry / Q000627:therapeutic use*; D006801:Humans; D010726:Phosphodiesterase Inhibitors / Q000737:chemistry / Q000627:therapeutic use*; D010727:Phosphoric Diester Hydrolases / Q000378:metabolism*; D012559:Schizophrenia / Q000188:drug therapy* / Q000201:enzymology; D012565:Schizophrenic Psychology; D015398:Signal Transduction / Q000187:drug effects; D016896:Treatment Outcome
D015507:Drugs, Investigational; D010726:Phosphodiesterase Inhibitors; D000242:Cyclic AMP; D010727:Phosphoric Diester Hydrolases